Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission

• Main Authors: Scott C. Olson, Nicole Ngo-Giang-Huong, Ingrid Beck, Wenjie Deng, Paula Britto, David E. Shapiro, Roger E. Bumgarner, James I. Mullins, Russell B. Van Dyke, Gonzague Jourdain, Lisa M. Frenkel
• Format: Journal
• Published: 2018
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942606205&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/54572
• Institution: Chiang Mai University

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. To prevent mother-to-child-transmission of HIV-1, the 2010 WHO guidelines recommended prenatal zidovudine (ZDV) monotherapy (option A). To determine if ZDV monotherapy selects for HIV resistance in antiretroviral-naive women during pregnancy, specimens from 50 individuals were examined using pyrosequencing. ZDVresistance mutations were detected at delivery in seven women (14%, 95% confidence interval 6.6-26.5%). These data raise the question whether women administered ZDV monotherapy for prevention of mother-to-child-transmission could have higher risk of virologic failure when later started on combination antiretroviral therapy, as has been demonstrated following single-dose nevirapine prophylaxis.